Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry. There are only 4 site visits by patients with minimal assessments over a 2-month period, and patients completing this study will have the ability to continue receiving SD-101-6.0 at home in an open-label extension study. The drug product and placebo require no special preparation or storage conditions (room temperature).

NCT Number	NCT07482787
Lead Sponsor	Paradigm Therapeutics
Conditions	Epidermolysis Bullosa (EB)
Enrollment	80 participants
Start Date	2026-07-21
Primary Completion	2027-05-17 (estimated)
Study Completion	2027-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-08-13